What medications should be started after a suicide attempt?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications After a Suicide Attempt

For patients after a suicide attempt, start cognitive behavioral therapy-based psychotherapy as the primary intervention, and consider ketamine infusion as adjunctive treatment for acute suicidal ideation in those with major depressive disorder, or clozapine for patients with schizophrenia/schizoaffective disorder who have ongoing suicidal ideation or prior attempts.

Primary Treatment Framework

The 2024 VA/DoD guidelines provide the most current evidence-based approach 1. The strongest recommendation is for CBT-based psychotherapy focused on suicide prevention (strong recommendation) for patients with suicidal behavior in the past 6 months 1. This should be your first-line intervention, not medication.

Medication Considerations by Clinical Context

For Acute Suicidal Ideation with Major Depressive Disorder

  • Ketamine infusion is suggested as adjunctive treatment for short-term reduction in suicidal ideation 1
  • This provides rapid relief (within hours to days) compared to traditional antidepressants which take weeks 2
  • Important caveat: There is insufficient evidence that ketamine reduces actual suicide attempts or completed suicide 1

For Schizophrenia or Schizoaffective Disorder

  • Clozapine is recommended to reduce suicide attempt risk in patients with ongoing suicidal ideation or history of attempts 1
  • This is the only FDA-approved medication specifically for reducing recurrent suicidal behavior 2

For Mood Disorders (Bipolar/Unipolar Depression)

  • Lithium has insufficient evidence despite historical use - the guidelines shifted from weak support to insufficient evidence 1
  • Traditional antidepressants show complex patterns: 50% of patients presenting with suicidal ideation were already on antidepressants, with a spike in new prescriptions the month before ED presentation 3

Critical Safety Considerations

Avoid prescribing medications that are lethal in overdose:

  • Minimize or eliminate tricyclic antidepressants - these were decreased post-ED presentation in real-world practice 3
  • Reduce opioid prescriptions (though 21% still received them post-attempt, which is problematic) 3
  • Benzodiazepines and opioids are the most frequently used in suicide attempts 4

Medications associated with increased suicidal ideation reports include:

  • Alprazolam, zolpidem, amphetamine, quetiapine, and fluoxetine showed highest reporting odds ratios 5
  • Exercise particular caution in patients under age 21, where antidepressants show age-related acute worsening of suicidal ideation 2

Post-Discharge Management Algorithm

  1. Immediate (First Week):

    • Initiate or continue CBT-based psychotherapy 1
    • If hospitalized with acute SI and MDD: consider ketamine infusion 1
    • Review current medications and eliminate high-lethality options 3
  2. First Month:

    • Send periodic caring communications (postal mail, text messages) for 12 months to reduce repeat attempts 1
    • Monitor closely as this is a high-risk period - patients often seek help in the month prior to presentation 3
  3. Ongoing:

    • Continue CBT or problem-solving therapies 1
    • For schizophrenia/schizoaffective: initiate clozapine if not contraindicated 1
    • Consider self-guided digital interventions with CBT content for ongoing SI reduction 1

What NOT to Do

  • Do not rely on risk stratification tools alone - insufficient evidence supports any specific tool 1
  • Do not assume safety planning alone is sufficient - insufficient evidence it reduces attempts 1
  • Do not prescribe dialectical behavior therapy expecting suicide reduction - insufficient evidence despite popularity 1
  • Do not use repetitive transcranial magnetic stimulation for suicide risk reduction - insufficient evidence 1

The Evidence Hierarchy

The 2025 VA/DoD guidelines 1 represent the highest quality, most recent evidence and should guide all decisions. Notably, psychotherapy receives stronger recommendations than any medication except in specific diagnostic contexts (schizophrenia for clozapine, MDD with acute SI for ketamine). The shift away from lithium recommendations and the cautious stance on commonly used interventions like safety planning reflects the evolving and often disappointing evidence base for suicide prevention interventions.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.